Clinical Trial Update: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy [Phase 1]

View source ↗

Summary

This Phase 1 study of veliparib in patients with malignant solid tumors that did not respond to prior therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal-like Breast Cancer
• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier | Phase 1 | Status: COMPLETED